{
  "id": "immunosuppression",
  "title": "Immunosuppression",
  "lang": "en",
  "source_lang": "en",
  "summary": "Immunosuppression is reduced immune activity caused by disease, treatment, or biological regulation, with important roles in transplantation and inflammatory disease.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Immune suppression",
    "suppression of immune function"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/immunosuppression/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/immunosuppression/",
      "json": "https://aiwiki.page/zh/immunosuppression.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Immunosuppression is a reduction in the activity or effectiveness of the immune system. It may be deliberately induced to prevent rejection of a transplanted organ or control harmful immune responses, or arise from illness, infection, malnutrition, or treatment directed at another condition. Its effects range from selective inhibition of one signaling pathway to extensive impairment of several immune defenses. The term overlaps with immunodeficiency, which describes inadequate immune protection, but often emphasizes the process that reduces immune activity rather than the resulting disorder.\n\nTherapeutic immunosuppression has made long-term organ transplantation possible and transformed the treatment of many inflammatory diseases. Its central limitation is that immune mechanisms responsible for tissue damage also contribute to protection against infection and cancer. Consequently, the effects of immunosuppression depend not only on its intensity but also on which immune functions are affected, how long suppression lasts, and the underlying condition of the individual."
    },
    {
      "heading": "Biological basis and distinctions",
      "text": "The immune system contains interacting innate and adaptive defenses. Innate defenses include epithelial barriers, phagocytic cells, natural killer cells, and soluble proteins that recognize or contain invading organisms. Adaptive immunity depends principally on lymphocytes: T cells coordinate responses and kill infected cells, while B cells produce antibodies. Immunosuppression can interfere with the production, activation, movement, survival, or communication of these cells. A treatment that reduces lymphocyte proliferation therefore has different consequences from one that lowers neutrophil numbers or blocks a single inflammatory messenger.\n\nT-cell activation illustrates several important therapeutic targets. A T cell recognizes an antigen presented by another cell, receives additional costimulatory signals, and responds to cytokines that support proliferation and differentiation. Calcineurin inhibitors interrupt intracellular signaling required for production of interleukin-2. Costimulation blockers interfere with interactions between antigen-presenting cells and T cells. Other drugs inhibit nucleotide synthesis or growth pathways, reducing the expansion of activated lymphocytes. These interventions suppress overlapping but nonidentical stages of an immune response.\n\nPhysiological immune regulation is not necessarily pathological immunosuppression. Regulatory T cells, inhibitory receptors, and mediators such as interleukin-10 normally restrict excessive responses and help maintain homeostasis. Immune tolerance is the more specific absence or control of a response to a particular antigen, including the body’s own tissues. A person can therefore be tolerant of one antigen while retaining strong responses to others. By contrast, many immunosuppressive treatments reduce responses to numerous unrelated antigens. T-cell exhaustion, which develops during some persistent infections and cancers, is another distinct state involving altered cellular function rather than simply fewer immune cells.\n\nImmunosuppression also differs from anti-inflammatory activity. Inflammation involves vascular changes, immune-cell recruitment, and signaling that can occur with or without an adaptive immune response. Nonsteroidal anti-inflammatory drugs reduce pain and inflammation but generally do not cause the broad immune impairment associated with transplantation regimens. Conversely, a drug that depletes B cells may substantially weaken antibody responses without producing an obvious immediate change in everyday symptoms.\n\nThere is no single biological scale on which all forms of immunosuppression can be ranked. The relevant dimensions include affected cell populations, functional impairment, tissue distribution, duration, and reversibility. Blood-cell counts may remain normal despite profound inhibition of cellular signaling, while a low count does not by itself describe every aspect of immune competence."
    },
    {
      "heading": "Causes outside deliberate immunosuppressive treatment",
      "text": "Immunosuppression can result from acquired disease, nutritional deficiency, tissue injury, or therapies whose main purpose is not immune suppression. It is usually distinguished from inborn errors of immunity, which arise from genetic abnormalities affecting immune development or function. These categories can overlap in practice: a person with an inherited defect may also acquire additional immune impairment from infection or treatment. The distinction concerns the cause, not necessarily the severity of the resulting susceptibility.\n\nHIV infection is a major example of acquired immune impairment. HIV infects cells expressing the CD4 receptor, and untreated infection progressively disrupts CD4 T-cell numbers and function. This compromises coordination of cellular and antibody-mediated responses. Advanced disease permits infections and malignancies that are uncommon in people with intact immunity. Effective antiretroviral therapy suppresses viral replication and often allows substantial immune recovery, although the extent and timing of recovery vary.\n\nHematological malignancies can impair immunity before treatment begins. Chronic lymphocytic leukemia can be associated with reduced immunoglobulin production, while multiple myeloma commonly suppresses production of normal antibodies despite abundant production of a monoclonal immunoglobulin. In leukemia, abnormal cells may disrupt normal blood-cell production in the bone marrow. Cytotoxic chemotherapy and some forms of radiation therapy can add further suppression by damaging rapidly dividing immune precursors.\n\nSevere malnutrition affects barrier integrity, lymphoid tissues, and immune-cell function. Advanced liver disease and chronic kidney disease also produce complex defects in immune defense. In sepsis, marked inflammation can coexist with impaired antigen presentation, lymphocyte loss, and reduced responsiveness to subsequent infection. This illustrates why excessive inflammation and immunosuppression are not mutually exclusive states.\n\nOther conditions require more precise terminology. Aging produces immunosenescence, including reduced production of new naïve T cells and altered responses to unfamiliar antigens, rather than uniform shutdown of immunity. Pregnancy involves coordinated, tissue-specific immune adaptation and is not accurately described as generalized immunosuppression. Likewise, diabetes mellitus can increase infection susceptibility through interacting metabolic, vascular, and immune mechanisms, but does not reproduce the pattern caused by lymphocyte-depleting treatment. Recognizing these differences is important because the type of immune defect helps explain which infections occur and how immune function may recover."
    },
    {
      "heading": "Major classes of immunosuppressive drugs",
      "text": "Immunosuppressive drugs differ in molecular target, breadth of action, speed of onset, and persistence after treatment ends. Glucocorticoids, including prednisone, act through intracellular receptors that alter gene expression. Their effects include reduced production of inflammatory mediators, altered leukocyte trafficking, and inhibition of multiple immune-cell functions. A rise in circulating neutrophil counts during glucocorticoid treatment can occur through redistribution and does not imply improved antimicrobial defense.\n\nCalcineurin inhibitors include cyclosporine and tacrolimus. Cyclosporine binds cyclophilin, whereas tacrolimus binds FK-binding protein 12; the resulting complexes inhibit calcineurin. This prevents activation of transcription factors needed for interleukin-2 production and other T-cell responses. These drugs are central to many transplantation regimens. Their clinical effects are constrained by narrow therapeutic ranges, variable exposure, and adverse effects including nephrotoxicity. Although sirolimus also binds FK-binding protein 12, it acts on a different pathway.\n\nAntimetabolites interfere with the synthesis or use of nucleotides needed for cell division. Azathioprine is converted into thiopurine metabolites that affect purine metabolism. Mycophenolate inhibits inosine monophosphate dehydrogenase, limiting guanine nucleotide synthesis; activated lymphocytes are particularly dependent on this pathway. Methotrexate has dose-dependent actions: at the low weekly doses used in inflammatory disease, its effects involve several mechanisms, including changes in extracellular adenosine signaling, rather than simply the cytotoxic action associated with high-dose oncology regimens. Cyclophosphamide damages DNA and can strongly suppress proliferating immune cells.\n\nSirolimus and everolimus inhibit mechanistic target of rapamycin signaling, restricting cellular responses to growth signals. Targeted small molecules also include Janus kinase inhibitors, which interfere with intracellular signaling downstream of several cytokine receptors. Their selectivity is relative rather than absolute, and their clinical effects depend on the kinases inhibited, exposure, and disease context.\n\nBiological agents target extracellular molecules or particular cell populations. A monoclonal antibody may neutralize tumor necrosis factor, block the interleukin-6 receptor, inhibit complement, or deplete CD20-positive B cells. Abatacept and belatacept use a fusion protein based on CTLA-4 to block CD80/CD86-mediated costimulation. Antithymocyte globulin contains antibodies against multiple lymphocyte antigens and can produce substantial T-cell depletion. Selectivity does not eliminate infection risk: suppressing one indispensable pathway may create a pronounced vulnerability to a limited set of pathogens. Drug combinations therefore produce an overall biological effect that cannot be inferred from the name or dose of a single agent."
    },
    {
      "heading": "Use in organ and stem-cell transplantation",
      "text": "Transplanted organs carry donor antigens that can be recognized by the recipient’s immune system. Human leukocyte antigen differences are especially important, although other donor molecules also contribute. Recipient T cells may recognize donor antigen-presenting cells directly or respond to donor-derived material processed by recipient cells. Antibodies can also damage graft blood vessels. Immunosuppression reduces these responses but usually does not eliminate their underlying potential, which is why many recipients require prolonged treatment.\n\nTransplantation regimens are commonly organized into induction, maintenance, and treatment of rejection. Induction therapy is administered around transplantation, when immune activation and the consequences of early rejection are substantial. It may involve a nondepleting interleukin-2 receptor antibody or a lymphocyte-depleting preparation. Maintenance frequently combines tacrolimus, an antimetabolite such as mycophenolate, and a glucocorticoid, although protocols vary by organ, recipient characteristics, and transplant center. Combining agents with different mechanisms can achieve stronger suppression without relying entirely on high exposure to one drug.\n\nThe required intensity changes over time. Early after transplantation, treatment is generally more intensive; later regimens reflect graft function, previous rejection, infection, toxicity, and other clinical findings. Transplant rejection can nevertheless occur years after transplantation, including after inadequate drug exposure. Antibody-mediated rejection presents additional complexity because long-lived plasma cells and established donor-specific antibodies may not be adequately controlled by treatments aimed mainly at T-cell activation. A biopsy often provides information needed to distinguish rejection from infection, drug injury, or other causes of graft dysfunction.\n\nIn hematopoietic stem-cell transplantation, the direction of immune attack can be reversed. Donor immune cells may attack recipient tissues, producing graft-versus-host disease. Immunosuppression is used both to prevent and to treat this complication. At the same time, donor immunity can attack residual malignant cells through the graft-versus-leukemia effect. Suppression may therefore reduce harmful tissue injury while also weakening a beneficial antitumor response.\n\nSuccessful engraftment does not imply immediate restoration of immunity. Recovery depends on donor-cell development, thymic function, prior conditioning, ongoing treatment, and complications. B-cell, T-cell, and innate immune recovery proceed at different rates. This makes immune status after stem-cell transplantation fundamentally different from that after transplantation of a kidney or liver, even when some of the same drugs are used."
    },
    {
      "heading": "Use in autoimmune and inflammatory disease",
      "text": "In autoimmune disease, immune responses directed against the body’s own components contribute to tissue injury. In other inflammatory disorders, immune activation is central even when a specific self-antigen has not been established. Immunosuppression can interrupt these processes, reduce symptoms, prevent structural damage, and preserve organ function. The therapeutic objective is usually control of harmful activity rather than abolition of immunity, and the appropriate biological target differs substantially among diseases.\n\nIn rheumatoid arthritis, persistent synovial inflammation can destroy cartilage and bone. Methotrexate and other disease-modifying drugs alter the disease process rather than acting only as analgesics. Tumor necrosis factor inhibitors, interleukin-6 receptor inhibitors, B-cell-depleting agents, costimulation blockers, and Janus kinase inhibitors target different components of the inflammatory network. Their differing mechanisms help explain why response to one treatment does not reliably predict response to another.\n\nSystemic lupus erythematosus illustrates the importance of organ involvement. Mild skin or joint disease and severe inflammatory kidney disease represent different treatment contexts. In lupus nephritis, immune complexes and inflammatory responses damage renal structures; treatment can involve glucocorticoids combined with mycophenolate or cyclophosphamide, with additional targeted agents used in defined settings. Disease control and treatment toxicity are assessed separately because reduced inflammatory activity does not automatically establish that accumulated organ damage has reversed.\n\nIn inflammatory bowel disease, treatment targets abnormal intestinal immune activity and its interaction with the epithelial barrier and microbiota. Some agents act systemically, while others are designed to concentrate their effects on intestinal lymphocyte trafficking or selected cytokines. Multiple sclerosis treatments provide another example of mechanistic diversity: different drugs alter lymphocyte movement, deplete particular cell populations, or modify signaling. They are not interchangeable forms of generalized immune suppression.\n\nNot every immune-modifying treatment is conventionally classified as an immunosuppressant. Hydroxychloroquine, for example, modifies antigen processing and innate immune signaling but does not have the same infection-risk profile as cytotoxic or lymphocyte-depleting therapy. The broader term “immunomodulation” accommodates treatments that redirect or normalize immune activity without uniformly depressing it. In inflammatory disease, immunosuppressive treatment can also improve health indirectly by controlling the underlying illness and reducing the need for prolonged high-dose glucocorticoids. Assessing net harm therefore requires separating the effects of the disease, the treatment, and concomitant medications."
    },
    {
      "heading": "Infection susceptibility and vaccination",
      "text": "Immunosuppression changes both the probability and the pattern of infection. Common community infections remain important, but particular immune defects also permit opportunistic infections that rarely cause invasive disease in immunocompetent people. Susceptibility depends on the organism, environmental exposure, immune pathway affected, and duration of impairment. In transplantation medicine, the “net state of immunosuppression” describes the combined influence of treatment, underlying illness, prior infections, barrier disruption, and other host factors.\n\nDifferent defects produce characteristic associations. Severe neutropenia increases the risk of invasive bacterial and fungal infections. Impaired T-cell immunity predisposes to Pneumocystis jirovecii pneumonia, certain fungal infections, and reactivation of latent viruses. B-cell depletion and reduced antibody concentrations can impair defense against encapsulated bacteria and weaken vaccine responses. Terminal complement inhibition creates a particular susceptibility to meningococcal disease. These patterns are useful clinically but are not absolute, especially when several immune defects coexist.\n\nLatent infection can become active when immune containment is disrupted. Tumor necrosis factor contributes to the maintenance of granulomatous responses, explaining the association between its inhibition and reactivation of tuberculosis. Hepatitis B can reactivate during several immunosuppressive regimens, with B-cell-depleting treatment representing an important risk setting. Cytomegalovirus can cause disease after transplantation, while BK polyomavirus can injure a transplanted kidney. The risks differ according to previous exposure, donor and recipient infection status, and treatment intensity.\n\nThe clinical appearance of infection may also change. Glucocorticoids and cytokine-blocking drugs can attenuate fever or inflammatory-marker responses. Consequently, the absence of a strong inflammatory reaction does not establish the absence of serious infection. Tissue-invasive disease may occur without the usual combination of symptoms, and several pathogens or noninfectious processes may coexist. Microbiological testing, imaging, and tissue examination therefore provide complementary rather than interchangeable information.\n\nVaccination in immunosuppressed populations involves both safety and effectiveness. Non-live vaccines cannot replicate in the recipient, but immune responses may be weaker or less durable. Live attenuated vaccines contain organisms capable of limited replication and can cause disease in some severely immunocompromised recipients. The degree and timing of suppression are therefore central to vaccination policies. B-cell-depleting therapy can markedly diminish new antibody responses, although some pre-existing antibodies may persist because long-lived plasma cells do not express CD20. Vaccination history alone consequently does not provide a complete measure of protection."
    },
    {
      "heading": "Malignancy and noninfectious adverse effects",
      "text": "The immune system contributes to control of oncogenic infections and recognition of abnormal cells. Sustained immunosuppression can weaken these functions and is associated with increased incidence of selected cancers, particularly after solid-organ transplantation. The increase is not uniform across all malignancies. Virus-associated tumors and certain skin cancers show especially strong associations, while risk also depends on age, ultraviolet exposure, smoking, previous treatment, and the duration and composition of immunosuppression.\n\nPost-transplant lymphoproliferative disorder comprises a spectrum of lymphoid proliferations arising after transplantation. Many cases are associated with Epstein–Barr virus, although EBV-negative disease also occurs. Impaired T-cell control permits expansion of infected B cells in important forms of the disorder. Risk is influenced by factors such as recipient EBV status, transplanted organ, and the intensity of T-cell suppression. Tissue examination is required to characterize the lesion because the spectrum includes biologically and clinically distinct conditions.\n\nCutaneous squamous-cell carcinoma is another major complication of long-term transplant immunosuppression. Its development reflects interactions among ultraviolet injury, reduced immune surveillance, and drug-specific effects. Some immunosuppressive drugs have direct effects on DNA damage responses or photosensitivity, while others alter cellular growth pathways. Cancer risk therefore cannot be explained solely as a single consequence of “low immunity.” Conversely, drugs that inhibit immune activity may also possess antineoplastic effects in particular settings, as illustrated by inhibitors of mechanistic target of rapamycin.\n\nNoninfectious toxicity often limits treatment independently of immune suppression. Calcineurin inhibitors can injure the kidney, raise blood pressure, and produce neurological adverse effects. Glucocorticoids can cause hyperglycemia, osteoporosis, cataracts, muscle weakness, and suppression of the hypothalamic–pituitary–adrenal axis. Mycophenolate commonly produces gastrointestinal adverse effects and can reduce blood-cell counts. Thiopurines can cause marrow suppression and liver injury. Cyclophosphamide has cumulative risks that include gonadal toxicity, bladder injury, and secondary malignancy.\n\nTargeted agents have distinct safety profiles rather than freedom from toxicity. Some Janus kinase inhibitors carry warnings concerning serious infections, thrombosis, malignancy, and cardiovascular events in defined patient populations. Certain drugs are embryo-fetal toxic, making reproductive effects a separate dimension of pharmacological safety. These outcomes must be distinguished from inadequate disease control: organ dysfunction may arise from the underlying disorder, infection, rejection, or drug injury. The same laboratory abnormality can consequently have several competing explanations, each with different implications for assessment."
    },
    {
      "heading": "Assessment, monitoring, and pharmacological variability",
      "text": "Assessment of immunosuppression combines the underlying diagnosis, treatment exposure, examination findings, laboratory data, and the history of infections or other complications. No routine test provides a complete numerical measure of immune competence. A normal complete blood count does not exclude defective lymphocyte signaling or impaired antibody responses, while reduced circulating cell numbers may not precisely reflect immune activity within tissues.\n\nBlood-cell counts identify leukopenia, neutropenia, and lymphopenia. Flow cytometry can quantify lymphocyte subsets, including CD4 T cells and circulating B cells. Immunoglobulin measurements help characterize humoral impairment, although concentration alone does not establish the functional quality or antigen specificity of antibodies. In selected settings, pathogen-specific tests, such as cytomegalovirus polymerase-chain-reaction assays, identify viral replication rather than measuring immunity directly. Their meaning depends on the assay, timing, patient population, and associated clinical findings.\n\nTherapeutic drug monitoring is particularly important for drugs with narrow therapeutic ranges and variable pharmacokinetics. Tacrolimus, cyclosporine, sirolimus, and everolimus are commonly assessed using concentrations measured at defined times relative to dosing. A concentration can help identify underexposure or excessive exposure, but does not directly measure suppression of the entire immune system. Even within a target concentration range, rejection, infection, or toxicity may occur.\n\nDrug interactions are a major source of variability. Tacrolimus and cyclosporine are affected by intestinal and hepatic drug-metabolizing systems and transporters. Some azole antifungals and macrolide antibiotics can raise concentrations, whereas strong enzyme-inducing drugs can lower them. Gastrointestinal illness, liver dysfunction, formulation changes, and inconsistent administration can also alter exposure. Genetic variation contributes further: CYP3A5 expression influences tacrolimus dose requirements, while variation in TPMT and NUDT15 can substantially affect susceptibility to thiopurine toxicity. These are established examples of pharmacogenomics, not universal predictors of treatment response.\n\nAssessment of therapeutic effect remains disease-specific. Transplant evaluation may include graft function, donor-specific antibodies, and histological findings. Inflammatory disease evaluation may combine symptoms, organ-specific measurements, inflammatory markers, and imaging. Investigational biomarkers, including donor-derived cell-free DNA and immune-response assays, aim to distinguish injury, rejection, and excessive suppression more accurately. Their interpretation remains context-dependent: a marker of tissue injury is not necessarily specific for rejection, and a marker associated with infection risk is not automatically a validated basis for changing treatment."
    },
    {
      "heading": "Historical development and research directions",
      "text": "Modern therapeutic immunosuppression emerged from the convergence of transplantation research, cancer chemotherapy, and studies of inflammatory disease. The anti-inflammatory effects of cortisone were demonstrated clinically in rheumatoid arthritis in 1948. The 1950 Nobel Prize in Physiology or Medicine recognized Edward Calvin Kendall, Tadeus Reichstein, and Philip Showalter Hench for discoveries concerning adrenal cortical hormones, their structure, and biological effects. Glucocorticoids subsequently became central tools for suppressing immune-mediated tissue injury.\n\nThe first successful long-term human kidney transplant, performed in Boston in 1954 between identical twins, avoided the major immunological barrier through genetic identity. Broader transplantation required methods to control responses between genetically different individuals. In the late 1950s and early 1960s, antimetabolites, especially azathioprine, helped establish pharmacological transplantation treatment. Combining azathioprine with corticosteroids made transplantation more feasible, although rejection, infection, and toxicity remained major limitations.\n\nCyclosporine marked a major shift because of its relatively selective effects on T-cell activation. Its immunosuppressive properties were identified in the early 1970s, and clinical development in the late 1970s and early 1980s substantially improved transplantation outcomes. Tacrolimus, mycophenolate, and increasingly specific biological agents later expanded the available combinations. The 1986 approval of muromonab-CD3 in the United States marked an early milestone in therapeutic monoclonal antibodies, although the drug was subsequently withdrawn from commercial use.\n\nLater development shifted toward distinguishing immune pathways rather than suppressing proliferating cells indiscriminately. Cytokine inhibitors transformed several inflammatory diseases, while costimulation blockade offered a different approach to transplantation. Advances in cancer immunotherapy revealed the converse problem: releasing immune inhibitory pathways with an immune checkpoint inhibitor can produce inflammatory adverse effects requiring immunosuppression. In transplant recipients, immune stimulation against cancer may also provoke graft rejection, exposing a direct conflict between antitumor immunity and graft protection.\n\nA major research objective is antigen-specific tolerance: durable control of harmful responses while preserving protection against unrelated pathogens. Investigational approaches include regulatory T-cell therapy, tolerogenic antigen-presenting cells, and mixed hematopoietic chimerism, in which donor and recipient blood-forming cells coexist. Selected transplantation studies have achieved substantial drug reduction or withdrawal, but these approaches carry limitations including conditioning toxicity, rejection, and graft-versus-host disease. Parallel research examines more selective delivery, tissue-specific immune regulation, and biomarkers that distinguish insufficient treatment from excessive suppression. The central experimental challenge is demonstrating durable functional protection rather than merely a temporary change in circulating immune-cell measurements."
    }
  ],
  "links": [
    "immune-system",
    "immunodeficiency",
    "organ-transplantation",
    "t-cell",
    "antibody",
    "cytokine",
    "interleukin-ten",
    "homeostasis",
    "t-cell-exhaustion",
    "inflammation",
    "hiv-aids",
    "chronic-lymphocytic-leukemia",
    "multiple-myeloma",
    "leukemia",
    "bone-marrow",
    "chemotherapy",
    "radiation-therapy",
    "malnutrition",
    "chronic-kidney-disease",
    "sepsis",
    "pregnancy",
    "diabetes-mellitus",
    "corticosteroid",
    "prednisone",
    "gene-expression",
    "monoclonal-antibody",
    "ctla-four",
    "transplant-rejection",
    "biopsy",
    "hematopoietic-stem-cell-transplantation",
    "graft-versus-host-disease",
    "graft-versus-leukemia-effect",
    "autoimmune-disease",
    "rheumatoid-arthritis",
    "systemic-lupus-erythematosus",
    "lupus-nephritis",
    "inflammatory-bowel-disease",
    "multiple-sclerosis",
    "hydroxychloroquine",
    "infectious-disease",
    "opportunistic-infection",
    "neutropenia",
    "tuberculosis",
    "hepatitis-b",
    "fever",
    "vaccine",
    "live-attenuated-vaccine",
    "epstein-barr-virus",
    "kidney",
    "osteoporosis",
    "complete-blood-count",
    "pharmacokinetics",
    "pharmacogenomics",
    "biomarker",
    "nobel-prize-in-physiology-or-medicine",
    "cancer-immunotherapy",
    "immune-checkpoint-inhibitor"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}